The FDA publicly promotes regulatory flexibility for rare diseases, yet industry insiders perceive it as less permissive than prior administrations. This disconnect between the agency's messaging and its actual decisions is fueling widespread criticism, investor uncertainty, and accusations of 'moving the goalposts'.

Disagreements between FDA review teams and senior leadership, like CBER head Vinay Prasad, create contradictory guidance for drug sponsors. Companies follow the review team's advice, only to be overruled by leadership, leading to wasted resources, delayed approvals, and significant frustration.

Facing a negative FDA decision, Replimune has filed a Freedom of Information Act (FOIA) request to investigate why senior FDA leadership allegedly overruled its own review team. This legalistic tactic moves beyond scientific debate into a public challenge of the agency's internal processes and transparency.

After the first FDA rejection, Replimune's chairman reveals they lacked funds to complete their confirmatory study to statistical significance. This forced them to submit a weaker "descriptive analysis" of early data for their second review—a high-risk gamble dictated by financial reality rather than an optimal regulatory strategy.

Despite the FDA leadership co-authoring an editorial supporting single-trial approvals, the industry is skeptical. The agency's recent inconsistent actions mean no executive or investor can confidently build a development strategy or financial model based on this policy, rendering the announcement largely ineffective.

The FDA issued guidance supporting minimal residual disease (MRD) as an approval endpoint in multiple myeloma. This directly contradicts the CBER division’s recent rejections of drugs based on single-arm response rates, creating a "schizophrenic" and unpredictable regulatory landscape for developers.

Replimune's core argument against the FDA's rejection is that the entire melanoma medical community is demanding access to their drug. The company highlights that 22 trial investigators and major medical institutions wrote letters to the FDA, attempting to use the weight of expert opinion to overrule the regulator's objections.

Recent events, like Moderna's rescinded 'refusal to file' letter, reveal that alignment with FDA staff on trial design is no guarantee. Senior leaders, notably Vinay Prasad, are reportedly overturning prior agreements, creating extreme uncertainty and making it impossible for companies to trust the regulatory guidance they receive.

The FDA's second Complete Response Letter for Replimune's advanced melanoma drug is a disappointing signal for the industry. Despite having what appeared to be a decent risk-benefit profile, the rejection suggests the regulatory bar for approvals based on single-arm studies remains unpredictably high and a head-scratcher for observers.